3/1/2011

Medtronic has agreed to partner with Nile Therapeutics to develop a peptide drug, called cenderitide, for heart failure and renal disease that can be delivered by its diabetes pump system. Under the agreement, Nile will focus on conducting a first-stage trial of the peptide, and Medtronic will provide financing and share its knowledge in developing drug-device combination products.

Related Summaries